Equities

Ventyx Biosciences Inc

VTYX:NSQ

Ventyx Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.37
  • Today's Change0.08 / 3.49%
  • Shares traded384.64k
  • 1 Year change-93.69%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.

  • Revenue in USD (TTM)0.00
  • Net income in USD-171.30m
  • Incorporated2018
  • Employees73.00
  • Location
    Ventyx Biosciences Inc12790 El Camino Real, Suite 200SAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 945-2393
  • Fax+1 (302) 655-5049
  • Websitehttps://ventyxbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Achieve Life Sciences Inc0.00-27.54m151.10m22.00--3.57-----1.10-1.100.001.230.00----0.00-58.78-86.31-71.94-119.59-----------11.790.294------29.60---14.51--
Actuate Therapeutics Inc0.00-27.77m152.89m6.00---------1.45-1.450.00-0.7114------0.00-------------------134.25---------22.74------
Skye Bioscience Inc0.00-42.29m158.97m11.00--2.02-----3.91-3.910.002.590.00----0.00-94.50-232.67-129.40-------------323.100.0626-------93.23--23.38--
Tenaya Therapeutics Inc0.00-120.74m159.36m140.00--1.19-----1.54-1.540.001.700.00----0.00-62.89---69.73--------------0.00-------0.3388------
Seres Therapeutics Inc374.00k-162.11m160.00m233.00------427.81-1.18-1.180.0027-0.57420.001--0.02861,605.15-44.53-41.51-59.82-54.13-----43,343.58-170.140.889-17.646.65--1,672.2434.9154.54--32.72--
Immunic Inc0.00-95.31m161.24m77.00--2.54-----1.51-1.510.000.70580.00----0.00-108.78-72.09-141.92-80.11------------0.00------22.25---10.97--
Ventyx Biosciences Inc0.00-171.30m161.83m73.00--0.5763-----2.79-2.790.003.970.00----0.00-52.07---55.27--------------0.00-------77.97------
P3 Health Partners Inc1.40bn-69.48m164.55m400.00--0.446--0.1173-0.5821-0.582111.561.031.56--10.973,507,143.00-20.51---110.70--0.62230.1781-13.17-56.93---9.670.2686--20.6770.5878.61---11.20--
Lineage Cell Therapeutics Inc6.19m-24.19m166.18m75.00--2.43--26.86-0.1342-0.13420.03430.36170.0577--18.2582,480.00-22.57-19.53-26.03-22.5990.8389.13-391.25-370.88----0.0017---39.1612.3918.22---27.16--
Capricor Therapeutics Inc27.15m-27.95m166.60m101.00--14.24--6.14-0.9302-0.93020.90720.35960.6443--59.18268,833.90-66.31-54.12-208.71-75.13-----102.93-316.25----0.2269--886.8172.0223.20--45.27--
Galectin Therapeutics Inc0.00-48.03m168.77m14.00---------0.7831-0.78310.00-1.320.00----0.00-185.54-92.08-382.33-121.97-----------8.598.29-------15.26------
Generation Bio Co13.17m-158.43m172.86m174.00--1.50--13.12-2.39-2.390.19891.730.0393--77.4975,712.64-47.28-36.96-51.64-39.21-----1,202.56-8,879.44----0.00----177.317.34--19.61--
Shattuck Labs Inc4.12m-85.28m174.20m75.00--1.57--42.24-1.85-1.850.08832.320.029----54,986.67-60.08-29.14-66.66-32.42-----2,067.99-565.33----0.00--154.14-40.6214.37---19.15--
Sangamo Therapeutics Inc12.28m-249.68m174.30m405.00--7.36--14.20-1.38-1.380.06640.11380.0587--7.4530,313.58-119.44-26.09-153.51-31.04-----2,033.68-136.53----0.00--58.3415.85-34.09---13.25--
Data as of Sep 19 2024. Currency figures normalised to Ventyx Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

45.01%Per cent of shares held by top holders
HolderShares% Held
Citadel Advisors LLCas of 30 Jun 20245.76m8.15%
Capital Research & Management Co. (International Investors)as of 30 Jun 20245.25m7.43%
BlackRock Fund Advisorsas of 30 Jun 20244.33m6.13%
Farallon Capital Management LLCas of 30 Jun 20243.17m4.49%
Tang Capital Management LLCas of 30 Jun 20243.10m4.39%
The Vanguard Group, Inc.as of 30 Jun 20242.95m4.17%
Octagon Capital Advisors LPas of 30 Jun 20242.39m3.38%
Redmile Group LLCas of 30 Jun 20242.16m3.06%
Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 20241.38m1.95%
Vestal Point Capital LPas of 30 Jun 20241.32m1.86%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.